Keywords: rigel, completes, ph, trail, ra, candidate, pharmaceuticals

Rigel completes Ph I trail of RA candidate

Article | 11 April 2005

Print This

Rigel Pharmaceuticals of the USA says that results from a recently-completed Phase I clinical study of R406, its oral rheumatoid ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in